These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 3025375)
1. Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations. Melamed E; Globus M; Mildworf B J Neurol Neurosurg Psychiatry; 1986 Nov; 49(11):1301-4. PubMed ID: 3025375 [TBL] [Abstract][Full Text] [Related]
2. Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa. Melamed E; Lavy S; Cooper G; Bentin S J Neurol Sci; 1978 Oct; 38(3):391-7. PubMed ID: 731264 [TBL] [Abstract][Full Text] [Related]
3. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease. Black KJ; Hershey T; Hartlein JM; Carl JL; Perlmutter JS Neuropsychopharmacology; 2005 Mar; 30(3):590-601. PubMed ID: 15602502 [TBL] [Abstract][Full Text] [Related]
4. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. Hershey T; Black KJ; Carl JL; McGee-Minnich L; Snyder AZ; Perlmutter JS J Neurol Neurosurg Psychiatry; 2003 Jul; 74(7):844-51. PubMed ID: 12810765 [TBL] [Abstract][Full Text] [Related]
5. [The effects of dopamine on regional cerebral blood flow in patients with Parkinson's disease before and after L-dopa--measurement by Xe-enhanced CT]. Aiba I; Indo T; Takahashi A Rinsho Shinkeigaku; 1994 Nov; 34(11):1099-104. PubMed ID: 7729088 [TBL] [Abstract][Full Text] [Related]
6. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257 [TBL] [Abstract][Full Text] [Related]
7. Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT. Sestini S; Ramat S; Formiconi AR; Ammannati F; Sorbi S; Pupi A J Nucl Med; 2005 Sep; 46(9):1444-54. PubMed ID: 16157526 [TBL] [Abstract][Full Text] [Related]
8. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements. Montastruc JL; Celsis P; Agniel A; Demonet JF; Doyon B; Puel M; Marc-Vergnes JP; Rascol A Mov Disord; 1987; 2(4):279-89. PubMed ID: 3509776 [TBL] [Abstract][Full Text] [Related]
9. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. Rascol O; Sabatini U; Chollet F; Fabre N; Senard JM; Montastruc JL; Celsis P; Marc-Vergnes JP; Rascol A J Neurol Neurosurg Psychiatry; 1994 May; 57(5):567-71. PubMed ID: 8201325 [TBL] [Abstract][Full Text] [Related]
10. Regional cerebral blood flow in hemiparkinsonian patients. Emission computerized tomography of inhaled 133Xenon before and after levodopa. Henriksen L; Boas J Acta Neurol Scand; 1985 Apr; 71(4):257-66. PubMed ID: 3873779 [TBL] [Abstract][Full Text] [Related]
11. Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease. Kishore A; Popa T; Velayudhan B; Joseph T; Balachandran A; Meunier S Brain; 2012 Jul; 135(Pt 7):2074-88. PubMed ID: 22609619 [TBL] [Abstract][Full Text] [Related]
12. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076 [TBL] [Abstract][Full Text] [Related]
13. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Harder S; Baas H; Rietbrock S Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026 [TBL] [Abstract][Full Text] [Related]
15. Local cerebral blood flow and its response to intravenous levodopa in progressive supranuclear palsy. Comparison with Parkinson's disease. Kobari M; Fukuuchi Y; Shinohara T; Nogawa S; Takahashi K Arch Neurol; 1992 Jul; 49(7):725-30. PubMed ID: 1497499 [TBL] [Abstract][Full Text] [Related]
16. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Mouradian MM; Juncos JL; Fabbrini G; Chase TN Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068 [TBL] [Abstract][Full Text] [Related]
17. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Chase TN Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164 [TBL] [Abstract][Full Text] [Related]
18. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. Imamura K; Okayasu N; Nagatsu T Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269 [TBL] [Abstract][Full Text] [Related]
19. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
20. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease. Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]